Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 15, 2024

Domatinostat Plus Avelumab for Previously Treated Mismatch Repair–Proficient Advanced Oesophagogastric and Colorectal Adenocarcinoma

ESMO Open

 

Additional Info

ESMO Open
Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE
ESMO Open 2024 Apr 01;9(4)102971, E Cartwright, S Slater, C Saffery, A Tran, F Turkes, G Smith, M Aresu, D Kohoutova, M Terlizzo, O Zhitkov, I Rana, EW Johnston, I Sanna, E Smyth, W Mansoor, C Fribbens, S Rao, I Chau, N Starling, D Cunningham

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading